Global Specialty Sales
$232M
+21% YoY
Global specialty sales grew 21% YoY to $232 million, driven by strong performance of ILUMYA and other products.
SUNPHARMA
Healthcare
10 Aug 2023
Sunpharma Ltd — Q1 FY24
Sun Pharma reported Q1 FY24 consolidated revenue of INR 11,785 crore, up 10.7% YoY, driven by US specialty growth (up 21% to $232M) and episodic lenalidomide sales.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Sun Pharma reported Q1 FY24 consolidated revenue of INR 11,785 crore, up 10.7% YoY, driven by US specialty growth (up 21% to $232M) and episodic lenalidomide sales. EBITDA grew 14.7% to INR 3,308 crore, with margins at 27.8%. India formulation sales grew 5.1% to INR 3,560 crore, impacted by NLEM and sitagliptin patent expiry. US generic sales rose 12% to $471M, but Mohali supplies remain suspended. Specialty pipeline advanced: GLP-1 agonist GL0034 showed promising Phase I data; ILUMYA Phase III for psoriatic arthritis accelerated; deuruxolitinib 8mg continues as planned. R&D spend was INR 680 crore (5.8% of sales). Management expects India growth to align with market in coming quarters. Key risk: Mohali plant restart timeline remains uncertain, potentially impacting US generic revenue.
सन फार्मा ने पहली तिमाही में 11,785 करोड़ रुपये की कमाई की, जो पिछले साल से 10.7% ज्यादा है। अमेरिका में खास दवाओं की बिक्री 21% बढ़कर 232 मिलियन डॉलर हुई और लेनालिडोमाइड दवा ने भी अच्छा योगदान दिया। कंपनी का मुनाफा 14.7% बढ़कर 3,308 करोड़ रुपये रहा। भारत में दवा बिक्री 5.1% बढ़ी, लेकिन सरकारी सूची में बदलाव और सीताग्लिप्टिन दवा के पेटेंट खत्म होने से असर पड़ा। अमेरिका में जेनेरिक दवाओं की बिक्री 12% बढ़ी, लेकिन मोहाली प्लांट से सप्लाई अभी बंद है। कंपनी ने नई दवाओं पर काम जारी रखा है। आरएंडडी पर 680 करोड़ रुपये खर्च हुए। आगे भारत में बिक्री बाजार के हिसाब से बढ़ने की उम्मीद है। मोहाली प्लांट खुलने में देरी से अमेरिकी कमाई पर असर पड़ सकता है।
Key Numbers
US Formulation Sales
$471M
+12% YoY
US formulation sales increased 12% YoY to $471 million, supported by specialty growth and lenalidomide.
India Market Share
8.33%
-17bps YoY
Sun Pharma's India market share declined to 8.33% from 8.5% a year ago, per AIOCD-AWACS MAT June 2023.
R&D Spend as % of Sales
5.8%
+150bps YoY
R&D spend increased to 5.8% of sales from 4.3% in Q1 FY23, driven by specialty pipeline investment.
Management Guidance
R&D spend guidance maintained at ~6-7% of sales for FY24
Management reiterated full-year R&D guidance, with potential updates if needed. Concert Pharma costs are included.
Management guidance growthIndia business to grow in line with or better than market in coming quarters
CEO Kirti Ganorkar expressed confidence that India formulation growth will align with IPM growth, recovering from NLEM and sitagliptin impacts.
Management guidance revenueLenalidomide sales expected to remain episodic
CFO noted that lenalidomide sales were significant in Q1 but will be episodic going forward, not a steady revenue stream.
Management guidance revenueDeuruxolitinib 8mg filing on track; no slowdown in OLE studies
Management confirmed that the partial clinical hold on 12mg has been lifted, and 8mg dosing continues as planned with no delays.
Management guidance otherKey Risks
Mohali plant supply suspension continues
Supplies from Mohali have not resumed; residual inventory sales are declining. Market share loss may be permanent depending on competition and contracts.
high · analyst_questionIndia market share decline and NLEM impact
India market share fell to 8.33% from 8.5% due to NLEM price cuts and sitagliptin patent expiry. Recovery timeline uncertain.
medium · management_commentaryTaro acquisition uncertainty
Management provided no update on the Taro minority buyout beyond forming a special committee. Strategic benefits remain unclear.
medium · analyst_questionSpecialty R&D pipeline execution risk
Multiple Phase II/III trials (ILUMYA PsA, deuruxo, GLP-1) require significant investment. Failure or delay could impact returns.
medium · data_observationNotable Quotes
We are quite excited with these early results and plan to initiate phase II clinical trials to start shortly.
As a standalone company, it will be very difficult for Taro as an independent company to continue to operate that business profitably.
We haven't seen any negative impact because of the entry of the HUMIRA biosimilars.
Frequently Asked Questions
What was Sunpharma's revenue in Q1 FY24?
Sunpharma reported revenue of ₹11,785 Cr in Q1 FY24, representing a +10.7% change compared to the same quarter last year.
What guidance did Sunpharma management give for FY25?
R&D spend guidance maintained at ~6-7% of sales for FY24: Management reiterated full-year R&D guidance, with potential updates if needed. Concert Pharma costs are included. India business to grow in line with or better than market in coming quarters: CEO Kirti Ganorkar expressed confidence that India formulation growth will align with IPM growth, recovering from NLEM and sitagliptin impacts. Lenalidomide sales expected to remain episodic: CFO noted that lenalidomide sales were significant in Q1 but will be episodic going forward, not a steady revenue stream. Deuruxolitinib 8mg filing on track; no slowdown in OLE studies: Management confirmed that the partial clinical hold on 12mg has been lifted, and 8mg dosing continues as planned with no delays.
What are the key risks for Sunpharma in FY25?
Key risks include Mohali plant supply suspension continues — Supplies from Mohali have not resumed; residual inventory sales are declining. Market share loss may be permanent depending on competition and contracts.; India market share decline and NLEM impact — India market share fell to 8.33% from 8.5% due to NLEM price cuts and sitagliptin patent expiry. Recovery timeline uncertain.; Taro acquisition uncertainty — Management provided no update on the Taro minority buyout beyond forming a special committee. Strategic benefits remain unclear.; Specialty R&D pipeline execution risk — Multiple Phase II/III trials (ILUMYA PsA, deuruxo, GLP-1) require significant investment. Failure or delay could impact returns..
Did Sunpharma meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Sunpharma Q1 FY24 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.